Munger Mode rating: 2 out of 5 — Sell. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
We are writing as Warren and Charlie. This is an independent conclusion based on regulatory filings, company results and calls, and the post-filing news flow. It uses no one's portfolio positions. Biogen is an average pharmaceutical business at a fair-to-full price. It is not a bad company. It earns real cash, its balance sheet is serviceable, and its new products are growing. But the profit pool we are being asked to pay for sits on a base that is eroding, and the management team keeps having to buy new growth to replace the old. What would change our mind: a price near $170–190, or clear Phase 3 evidence that litifilimab and felzartamab can replace the multiple sclerosis (MS) franchise's lost earnings. The first litifilimab lupus data are expected in the first half of December 2026. We would not buy ahead of a coin-flip binary event.
Recent filings analysed: 10-Q (2026-10-28), 8-K (2026-10-28), 10-Q (2026-07-29), 8-K (2026-07-29).
Stock screener · Superinvestor 13F holdings · Analyst sentiment